Diagnostics News and Research

RSS

Advaxis updates preliminary data from ADXS-HPV Phase 2 trial on cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, updated preliminary data from an ongoing randomized 110 patient Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

1 Nov 2012

Affordable Medicines Facility improves access to anti-malarials

The Affordable Medicines Facility-malaria has resulted in significant improvements in the availability and price of quality-assured artemisinin-based combination therapies in seven African countries after 1 year, show study findings published in The Lancet.

31 Oct 2012

Access to malaria drugs transformed by new global subsidy

A new international scheme providing lifesaving antimalarial drugs at cheap subsidised prices has rapidly transformed access to effective artemisinin combination therapies (ACTs) in seven African countries accounting for a quarter of the world’s malaria cases, and could save millions of lives.

31 Oct 2012

Thermo Fisher launches Sorvall LYNX superspeed centrifuge series

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the new Thermo Scientific Sorvall LYNX superspeed centrifuge series, delivering productivity, safety and reliability to maximize everyday centrifuge use in shared laboratory settings.

From Thermo Fisher Scientific Inc. 31 Oct 2012

Breast cancer screening reduces deaths but overdiagnoses

An independent panel of experts has concluded that routine breast cancer screening results in a reduced risk of dying from breast cancer compared to when no screening takes place, but that screening also results in overdiagnosis, according to a Review published in The Lancet.

30 Oct 2012

Exact Sciences reports total revenues of $1.0 million for third quarter 2012

Exact Sciences Corp. today announced its financial results for the quarter ended Sept. 30, 2012.

30 Oct 2012

Luminex third quarter revenue increases 10% to $50.0 million

Luminex Corporation today announced financial results for the third quarter ended September 30, 2012.

From Luminex 30 Oct 2012

The App That's Transforming Blood Banking

An interview with Celia Tombalankian, discussing the benefits of automation in blood banking and the development of a new blood banking app.

From Ortho-Clinical Diagnostics, Inc. 29 Oct 2012

Haemonetics second quarter 2013 net revenue increases 22% to $218.2 million

Haemonetics Corporation today reported second quarter 2013 net revenue of $218.2 million, up 22%, GAAP net income of $6.5 million, down 53%, and diluted earnings per share of $0.25, down 53%.

29 Oct 2012

New HIV test for babies differs from conventional test, delivers diagnosis in less than an hour

Today, mothers in Africa sometimes walk more than 10 miles to a clinic only to learn that conventional HIV test results for their babies are not available yet.

29 Oct 2012

Study defines complexity of underlying mutations responsible for pancreatic cancers

A large-scale study that defines the complexity of underlying mutations responsible for pancreatic cancers in more than 100 patients was published in Nature today.

26 Oct 2012

Study confirms Elf5 protein as tumor suppressor of breast cancer

A protein that is necessary for lactation in mammals inhibits the critical cellular transition that is an early indicator of breast cancer and metastasis, according to research conducted at the University at Buffalo and Princeton University and highlighted as the cover paper in November issue of Nature Cell Biology.

25 Oct 2012

Abbott announces results from HUMIRA clinical studies on ulcerative colitis

Abbott (NYSE: ABT) today announced results from an analysis of three-year long-term data from an ongoing open-label extension of the HUMIRA (adalimumab) ULTRA 1 and ULTRA 2 studies.

23 Oct 2012

Talk explores improved diagnostics for cardiac threat through biomedical imaging

Each year, seemingly healthy people suffer from acute heart attacks, strokes and sudden cardiac death.

20 Oct 2012

AMP report provides overview of next generation sequencing technology

The Association for Molecular Pathology published the report of the Whole Genome Analysis Working Group of the AMP Clinical Practice Committee in the November 2012 issue of The Journal of Molecular Diagnostics.

20 Oct 2012

TB Alliance and FIND partner to promote development of TB drugs and diagnostics

A new partnership announced today will increase efforts to coordinate the development of complementary novel tools to fight TB, including drug-resistant TB, and identify emerging drug resistance trends around the globe.

19 Oct 2012

GENNET, BGI enter collaborative agreement for non-invasive fetal trisomy test

BGI, the world's largest genomics organization, and GENNET, a center for genetics, fetal medicine and assisted reproduction, jointly announced that they have entered a collaborative agreement on non-invasive fetal trisomy (NIFTY) test with the aim to significantly improve reproductive health in Czech and Slovak Republic. Th

17 Oct 2012

Thermo Fisher Scientific introduces MYECL Imager instrument

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific MYECL Imager, an easy-to-use imaging instrument that delivers one-touch image capture and analysis of protein and nucleic acid gels and Western blots.

From Thermo Fisher Scientific Inc. 17 Oct 2012

FDA approves Hologic’s APTIMA HPV 16 18/45 Genotype Assay for use on TIGRIS system

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's APTIMA HPV 16 18/45 Genotype Assay for use on its TIGRIS instrument system.

From Hologic, Inc. 16 Oct 2012

Hepatitis C rapid and point of care tests highly accurate and reliable

Timely screening and diagnosis is critical to the success of new treatments and ultimately to the survival of hepatitis C patients. A new study led by the Research Institute of the McGill University Health Centre (RI MUHC) is the first to show that hepatitis C rapid and point of care tests with a quick turnaround time are highly accurate and reliable as conventional first-line laboratory tests.

16 Oct 2012